Biomarin's dwarfism drug receives FDA approval

The growth hormone Voxzogo has been approved by the US Food and Drug Administration (FDA) as a treatment for achondroplasia in children.

Photo: Andrew Kelly/REUTERS / X02844

Biomarin's drug against achondroplasia, also known as dwarfism, has had a better start than most, and now the US-based biotech company can add another feather to its cap.

On Friday, the US Food and Drug administration (FDA) announced that it has granted the drug marketing approval, and thus the road has been cleared for Biomarin to reach the drug's biggest market in the world. The company is expecting to launch the Voxzogo in the US in mid-December.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs